Su-jin Kim1,2,3, Jun Pyo Myong4, Hyeon-Gun Jee1,2,3, Young Jun Chai1,2,3, June Young Choi5, Hye Sook Min6, Kyu Eun Lee1,2,3, Yeo-Kyu Youn1,2,3. 1. Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea. 2. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 3. Division of Surgery, Thyroid Center, Seoul National University Cancer Hospital, Seoul, Korea. 4. Department of Occupational and Environmental Medicine & Center for Occupational and Environmental Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. 5. Department of Surgery, Bundang Seoul National University Hospital, Seoul, Korea. 6. Department of Pathology, Seoul National University College of Medicine and Hospital, Seoul, Korea.
Abstract
BACKGROUND: The purpose of this study was to evaluate the association between Hashimoto's thyroiditis and BRAF(V600E) mutation status in patients with papillary thyroid cancer (PTC) and to determine their combined association with tumor aggressiveness in PTC. METHODS: A total of 1780 patients with PTC who underwent surgery were enrolled in this study. Simple and multiple analyses were performed to determine the association between Hashimoto's thyroiditis and the BRAF(V600E) mutation in PTC. RESULTS: Hashimoto's thyroiditis was present in 11.5% of patients (204/1780) with PTC. Multiple logistic regressions showed that BRAF(V600E) (odds ratio [OR] = 0.493; 95% confidence interval [CI] = 0.360-0.678) and the female sex (OR = 7.146; 95% CI = 3.408-18.347) were independent factors associated with Hashimoto's thyroiditis in PTC. BRAF(V600E) mutation and the Hashimoto's thyroiditis-negative PTC group were associated with aggressive disease (OR = 3.069; 95% CI = 1.654-5.916). CONCLUSION: Hashimoto's thyroiditis was associated less frequently with BRAF(V600E) , and frequently with the female sex in patients with PTC. Hashimoto's thyroiditis and BRAF(V600E) status may help to predict clinical outcome of PTC.
BACKGROUND: The purpose of this study was to evaluate the association between Hashimoto's thyroiditis and BRAF(V600E) mutation status in patients with papillary thyroid cancer (PTC) and to determine their combined association with tumor aggressiveness in PTC. METHODS: A total of 1780 patients with PTC who underwent surgery were enrolled in this study. Simple and multiple analyses were performed to determine the association between Hashimoto's thyroiditis and the BRAF(V600E) mutation in PTC. RESULTS:Hashimoto's thyroiditis was present in 11.5% of patients (204/1780) with PTC. Multiple logistic regressions showed that BRAF(V600E) (odds ratio [OR] = 0.493; 95% confidence interval [CI] = 0.360-0.678) and the female sex (OR = 7.146; 95% CI = 3.408-18.347) were independent factors associated with Hashimoto's thyroiditis in PTC. BRAF(V600E) mutation and the Hashimoto's thyroiditis-negative PTC group were associated with aggressive disease (OR = 3.069; 95% CI = 1.654-5.916). CONCLUSION:Hashimoto's thyroiditis was associated less frequently with BRAF(V600E) , and frequently with the female sex in patients with PTC. Hashimoto's thyroiditis and BRAF(V600E) status may help to predict clinical outcome of PTC.
Authors: Csaba Molnár; Sarolta Molnár; Judit Bedekovics; Attila Mokánszki; Ferenc Győry; Endre Nagy; Gábor Méhes Journal: Pathol Oncol Res Date: 2019-01-21 Impact factor: 3.201